Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
ESsCAPE
A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)
1 other identifier
interventional
590
17 countries
140
Brief Summary
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Sep 2023
Longer than P75 for phase_3
140 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 11, 2023
CompletedFirst Posted
Study publicly available on registry
February 10, 2023
CompletedStudy Start
First participant enrolled
September 9, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2028
February 17, 2026
February 1, 2026
4.9 years
January 11, 2023
February 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
28-day all-cause mortality rate
Percentage of subjects that died until day 29 regardless of cause of death
Between days 1-29
Secondary Outcomes (25)
90-day all-cause mortality rate
Between days 1-91
Deterioration rate (up to day 29)
Up to day 29
Change in Sequential Organ Failure Assessment (SOFA) score from baseline to day 7
Between baseline and Day 7
Proportion of subjects with clinical cure of pneumonia up to day 29
Up to day 29
Days of invasive mechanical ventilation (IMV) up to day 29
Up to day 29
- +20 more secondary outcomes
Other Outcomes (3)
Serum concentration of immunoglobulins
Day 1, 5, 14
Pharmacokinetic assessment of immunoglobulins
Day 1, 2, 3, 4, 5, 6, 7, 9, 14, 21, 29
Pharmacodynamic assessment of disease related serum proteins
Day 1, 2, 3, 4, 5, 7, 14, 21, 29
Study Arms (2)
Trimodulin
EXPERIMENTALTrimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
Placebo
PLACEBO COMPARATORHuman albumin 1%
Interventions
IMP will be administered via IV infusion on 5 consecutive days
Eligibility Criteria
You may qualify if:
- Written informed consent.
- Hospitalized, adult (≥ 18 years of age) subject.
- Signs of inflammation based on C-reactive protein threshold level.
- Diagnosis of active community-acquired pneumonia (CAP) before hospital-admission or within 48 hours after admission.
- Radiological (or other imaging technology) evidence consistent with active pneumonia.
- Acute respiratory failure requiring IMV.
You may not qualify if:
- Pregnant or lactating women.
- Subjects of childbearing potential not willing to use reliable contraceptive measures during the trial and for 15 weeks after the last IMP treatment.
- Subjects on ECMO at start of IMP treatment.
- Suspected hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP).
- Subjects discharged from hospital within the previous 14 days.
- Defined neutrophil counts up to one calendar day prior to start of IMP treatment.
- Defined platelet counts up to one calendar day prior to start of IMP treatment.
- Defined hemoglobin within up to one calendar day prior to start of IMP treatment.
- Pre-existing hemolytic disease.
- Thromboembolic events (TEEs) caused by other reasons than the current sCAP within 3 months before start of IMP treatment unless the risk for further TEEs can be adequately managed with standard prophylaxis or treatment.
- Severe renal impairment prior to start of IMP treatment.
- End-stage renal disease (ESRD) or known primary focal segmental glomerulosclerosis (FSGS).
- Pre-existing severe lung diseases concomitant to current sCAP (e.g. active tuberculosis, active lung cancer).
- Pre-existing decompensated heart failure.
- Pre-existing severe hepatic cirrhosis (Child Pugh score ≥ 10 points), or severe hepatic impairment (Child Pugh score ≥ 10 points), or hepatocellular carcinoma.
- +8 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Biotestlead
Study Sites (146)
Pulmonary Associates of Mobile, P.C.
Mobile, Alabama, 36608, United States
University of California San Francisco-Fresno
Fresno, California, 93701, United States
UC Davis Health
Sacramento, California, 95817, United States
Augusta University
Augusta, Georgia, 30912, United States
Sparrow Clinical Research Institute
Lansing, Michigan, 48912, United States
William Beaumont Hospital
Royal Oak, Michigan, 48073, United States
University of Missouri Clinical Research Center
Columbia, Missouri, 65212, United States
Hannibal Clinic
Hannibal, Missouri, 63401, United States
Mercury Street Medical Group
Butte, Montana, 59701, United States
St. Michael's Medical Center
Newark, New Jersey, 07102, United States
Buffalo VA Medical Center
Buffalo, New York, 14215, United States
Lenox Hill Hospital
New York, New York, 10075-1850, United States
Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
Jefferson University Hospitals
Philadelphia, Pennsylvania, 19107, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Medical City Fort Worth
Fort Worth, Texas, 76104, United States
Houston Methodist Hospital
Houston, Texas, 77030, United States
University of Utah
Salt Lake City, Utah, 84108, United States
Sanatorio Parque S.A. Privado
San Vicente, Córdoba Province, 5006, Argentina
CEMIC
Ciudad Autonoma de Buenos Aire, 1431, Argentina
Sanatorio de la Trinidad Mitre
Ciudad Autonoma de Buenos Aire, C1039AAO, Argentina
Hospital Italiano de Buenos Aires
Ciudad Autonoma de Buenos Aire, C1181ACH, Argentina
Hospital General de Agudos Dr. Ignacio Pirovano
Ciudad Autonoma de Buenos Aire, C1430BKC, Argentina
Clinica Adventista Belgrano
Ciudad Autonoma de Buenos Aire, C1430EGF, Argentina
Clinica Chutro
Córdoba, 5000, Argentina
Hospital San Roque
Córdoba, 5000, Argentina
Sanatorio Privado de la Canada - Cordoba
Córdoba, X5000BSQ, Argentina
Centro Medico IPAM
Rosario, S2001SBK, Argentina
Estudios Clinicos de los Arroyos
San Nicolás, 2900, Argentina
Sanatorio de la Canada
Villa María, 5900, Argentina
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
Monash Medical Centre
Clayton, Victoria, 3168, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
Footscray Hospital
Footscray, 3011, Australia
Austin Health
Heidelberg, 3084, Australia
Sunshine Hospital
Saint Albans, 3021, Australia
KABEG-Klinikum Klagenfurt
Klagenfurt, 9020, Austria
AKH - Medizinische Universität Wien
Vienna, 1090, Austria
Onze Lieve Vrouw Ziekenhuis
Aalst, 9300, Belgium
AZ Sint-Jan
Bruges, 8000, Belgium
Hopital Erasme
Brussels, 1070, Belgium
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
Antwerp University Hospital (UZA)
Edegem, 2650, Belgium
ZOL
Genk, 3600, Belgium
AZ Maria Middelares
Ghent, 9000, Belgium
Universitair Ziekenhuis Brussel
Jette, 1090, Belgium
C. H. R. de la Citadelle
Liège, 4000, Belgium
CHU Charleroi Hôpital Civil Marie Curie
Lodelinsart, 6042, Belgium
Clinique Saint-Pierre
Ottignies, 1340, Belgium
AZ Delta VZW
Roeselare, 8800, Belgium
UPECLIN - Unidade de Pesquisa Clínica
Botucatu, 18618-686, Brazil
HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas
Campinas, 13060-904, Brazil
Hospital do Rocio
Campo Largo, 83606-177, Brazil
Universidade de Caxias do Sul, IPCEM - Instituto de Pesquisa Clínica para Estudos Multicêntricos
Caxias do Sul, 95070-560, Brazil
Hospital de Clínicas de Passo Fundo
Passo Fundo, 99010-260, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, 90020-090, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, 90035-903, Brazil
Hospital Ernesto Dornelles
Porto Alegre, 90160-093, Brazil
CIP - Centro Integrado de Pesquisa
São José do Rio Preto, 15090-000, Brazil
Hospital Alemão Oswaldo Cruz
São Paulo, 01323-020, Brazil
Universidade Municipal de Sao Caetano do Sul (USCS)
São Paulo, 09530-700, Brazil
Fakultni nemocnice u sv. Anny v Brne
Brno, 65691, Czechia
Oblastni nemocnice Kolin a.s.
Kolín, 28002, Czechia
Hospital Kyjov
Kyjov, 69701, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, 10034, Czechia
Centre Hospitalier Victor Dupouy
Argenteuil, 95107, France
Hôpital Louis Mourier
Colombes, 92700, France
CHU de Grenoble - Hôpital Albert Michallon
Grenoble, 38043, France
CHRU Lille - Hôpital Salengro
Lille, 59037, France
CHU de Limoges - Hôpital Dupuytren
Limoges, 87000, France
Centre Hospitalier de Melun
Melun, 77000, France
CHU Nice-Hopital de l' Archet
Nice, 06202, France
CHU Nice Hopital Pasteur 2
Nice, 6100, France
Hôpital Bichat - Claude Bernard
Paris, 75018, France
Groupe Hospitalier Diaconesses - Hopital De La Croix Saint Simon
Paris, 75020, France
Hôpital Tenon
Paris, 75020, France
Hôpital Cochin
Paris, 75679, France
CHU Reims - Hôpital Robert Debré
Reims, 51100, France
CHU Rennes - Hôpital Pontchaillou
Rennes, 35000, France
CHU Saint-Etienne
Saint-Etienne, 42055, France
CHU Strasbourg - Nouvel Hôpital Civil
Strasbourg, 67091, France
CHU Strasbourg - Hôpital Hautepierre
Strasbourg, 67098, France
Hôpital Sainte Musse
Toulon, 83056, France
CHU Tours - Hôpital Bretonneau
Tours, 37000, France
Hôpital Nord Franche-Comté
Trévenans, 90400, France
Charité Universitätsmedizin Berlin - Campus Charité Mitte
Berlin, 10117, Germany
Universitaetsklinikum Essen
Essen, 45147, Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, 79106, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246, Germany
Medizinische Hochschule Hannover
Hanover, 30625, Germany
Bugat Pal Korhaz
Gyöngyös, 3200, Hungary
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
Gyula, 5700, Hungary
Pest Megyei Flor Ferenc Korhaz
Kistarcsa, 2143, Hungary
Aneszteziologiai es Intenziv Terapias Intezet
Pécs, 7624, Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
Szeged, 6725, Hungary
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
Székesfehérvár, 8000, Hungary
St James's Hospital
Dublin, D08NYH1, Ireland
Beaumont Hospital
Dublin, D09 V2N0, Ireland
St Vincents University Hospital
Dublin, Dublin 4, Ireland
University Hospital Galway
Galway, H91YR71, Ireland
Soroka Medical Center
Beersheba, 8410101, Israel
Bnai Zion Medical Center
Haifa, 31048, Israel
Rambam Medical Center
Haifa, 31096, Israel
The Lady Davis Carmel Medical Center
Haifa, 3436212, Israel
Rabin Medical Center
Petah Tikva, 4941492, Israel
Kaplan Medical Center
Rehovot, 761001, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
Middlemore Hospital
Otahuhu, 2025, New Zealand
Capital, Coast and Hutt Valley District - Wellington Regional Hospital
Wellington, 6021, New Zealand
Baguio General Hospital and Medical Center
Baguio City, 2600, Philippines
Dr. Jose N. Rodriguez Memorial Hospital
Caloocan, 1427, Philippines
Davao Doctors Hospital
Davao City, 8000, Philippines
Southern Philippines Medical Center
Davao City, 8000, Philippines
St.Paul's Hospital
Iloilo City, 5000, Philippines
West Visayas State University Medical Center
Iloilo City, 5000, Philippines
Philippine General Hospital
Manila, 1000, Philippines
Lung Center of the Philippines
Quezon City, 1100, Philippines
Institutul Clinic Fundeni
Bucharest, 022328, Romania
Spitalul Universitar de Urgenta Bucuresti
Bucharest, 050098, Romania
Spitalul Clinic Judetean de Urgenta "Pius Brinzeu"
Timișoara, 300723, Romania
Johese Clinical Research
Centurion, Gauteng, 0157, South Africa
Emmed Clinical Research
Pretoria, Gauteng, 0002, South Africa
Into Research
Pretoria, Gauteng, 0181, South Africa
Worthwhile Clinical Trials
Johannesburg, 1500, South Africa
RYEXO Clinical Research Zuid Afrikaans Hospital
Pretoria, 0002, South Africa
RYEXO Clinical Research
Pretoria, 0184, South Africa
Dr JM Engelbrecht Trial Site
Somerset West, 7130, South Africa
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
Hospital de la Santa Creu i de Sant Pau
Barcelona, 08041, Spain
Hospital Universitari Vall d'Hebrón
Barcelona, 8035, Spain
Hospital Universitari de Bellvitge
Barcelona, 8907, Spain
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
Hospital Universitari de Girona Dr Josep Trueta
Girona, 17007, Spain
Hospital Universitario Clinico San Carlos
Madrid, 28040, Spain
Hospital Universitario La Paz
Madrid, 28046, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, 28222, Spain
Hospital Universitario Son Espases
Palma de Mallorca, 07120, Spain
Clinica Universidad de Navarra
Pamplona, 31008, Spain
Hospital Universitari de Tarragona Joan XXIII
Tarragona, 43007, Spain
Hospital Universitari Mutua de Terrassa
Terrassa, 8221, Spain
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
Queen Elizabeth University Campus
Glasgow, G11 6NT, United Kingdom
Royal Surrey County Hospital
Guildford, GU2 7XX, United Kingdom
St Thomas' Hospital
London, SE1 7EH, United Kingdom
Derriford Hospital
Plymouth, PL6 8DH, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ricard Ferrer Roca, Dr.
Hospital Vall d'Hebron
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- All bottles will be indistinguishable.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 11, 2023
First Posted
February 10, 2023
Study Start
September 9, 2023
Primary Completion (Estimated)
July 31, 2028
Study Completion (Estimated)
July 31, 2028
Last Updated
February 17, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share